HIC1 interacts with and modulates the activity of STAT3

References

• Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995; 1:570 - 7; http://dx.doi.org/10.1038/nm0695-570; PMID: 7585125
   PubMed Web of Science ®Google Scholar
• Boulay G, Dubuissez M, Van Rechem C, Forget A, Helin K, Ayrault O, et al. Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins. J Biol Chem 2012; 287:10509 - 24; http://dx.doi.org/10.1074/jbc.M111.320234; PMID: 22315224
   PubMed Web of Science ®Google Scholar
• Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D. The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol Cell Biol 2002; 22:4890 - 901; http://dx.doi.org/10.1128/MCB.22.13.4890-4901.2002; PMID: 12052894
   PubMed Web of Science ®Google Scholar
• Stankovic-Valentin N, Verger A, Deltour-Balerdi S, Quinlan KG, Crossley M, Leprince DA. A L225A substitution in the human tumour suppressor HIC1 abolishes its interaction with the corepressor CtBP. FEBS J 2006; 273:2879 - 90; http://dx.doi.org/10.1111/j.1742-4658.2006.05301.x; PMID: 16762039
   PubMed Web of Science ®Google Scholar
• Van Rechem C, Boulay G, Pinte S, Stankovic-Valentin N, Guérardel C, Leprince D. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 2010; 30:4045 - 59; http://dx.doi.org/10.1128/MCB.00582-09; PMID: 20547755
   PubMed Web of Science ®Google Scholar
• Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guérardel C, Leprince D. The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 2004; 279:38313 - 24; http://dx.doi.org/10.1074/jbc.M401610200; PMID: 15231840
   PubMed Web of Science ®Google Scholar
• Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123:437 - 48; http://dx.doi.org/10.1016/j.cell.2005.08.011; PMID: 16269335
   PubMed Web of Science ®Google Scholar
• Dehennaut V, Loison I, Dubuissez M, Nassour J, Abbadie C, Leprince D. DNA double-strand breaks lead to activation of hypermethylated in cancer 1 (HIC1) by SUMOylation to regulate DNA repair. J Biol Chem 2013; 288:10254 - 64; http://dx.doi.org/10.1074/jbc.M112.421610; PMID: 23417673
   PubMed Web of Science ®Google Scholar
• Valenta T, Lukas J, Doubravska L, Fafilek B, Korinek V. HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. EMBO J 2006; 25:2326 - 37; http://dx.doi.org/10.1038/sj.emboj.7601147; PMID: 16724116
   PubMed Web of Science ®Google Scholar
• Jove R. Preface: STAT signaling. Oncogene 2000; 19:2466 - 7; http://dx.doi.org/10.1038/sj.onc.1203549; PMID: 10851044
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Levy DE, Inghirami G. STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006; 103:10151 - 2; http://dx.doi.org/10.1073/pnas.0604042103; PMID: 16801534
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295 - 303; http://dx.doi.org/10.1016/S0092-8674(00)81959-5; PMID: 10458605
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr.. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2:740 - 9; http://dx.doi.org/10.1038/nrc906; PMID: 12360277
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474 - 88; http://dx.doi.org/10.1038/sj.onc.1203527; PMID: 10851046
   PubMed Web of Science ®Google Scholar
• Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197:157 - 68; http://dx.doi.org/10.1002/jcp.10364; PMID: 14502555
   PubMed Web of Science ®Google Scholar
• Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98:7319 - 24; http://dx.doi.org/10.1073/pnas.131568898; PMID: 11404481
   PubMed Web of Science ®Google Scholar
• Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97:4227 - 32; http://dx.doi.org/10.1073/pnas.97.8.4227; PMID: 10760290
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21:2000 - 8; http://dx.doi.org/10.1038/sj.onc.1205260; PMID: 11960372
   PubMed Web of Science ®Google Scholar
• Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63:3923 - 30; PMID: 12873986
   PubMed Web of Science ®Google Scholar
• Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182:855 - 63; http://dx.doi.org/10.1083/jcb.200806076; PMID: 18779368
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr.. STATs and gene regulation. Science 1997; 277:1630 - 5; http://dx.doi.org/10.1126/science.277.5332.1630; PMID: 9287210
   PubMed Web of Science ®Google Scholar
• Schindler C, Darnell JE Jr.. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64:621 - 51; http://dx.doi.org/10.1146/annurev.bi.64.070195.003201; PMID: 7574495
   PubMed Web of Science ®Google Scholar
• Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 2005; 280:11528 - 34; http://dx.doi.org/10.1074/jbc.M413930200; PMID: 15649887
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307:269 - 73; http://dx.doi.org/10.1126/science.1105166; PMID: 15653507
   PubMed Web of Science ®Google Scholar
• Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004; 279:821 - 4; http://dx.doi.org/10.1074/jbc.R300030200; PMID: 14607831
   PubMed Web of Science ®Google Scholar
• Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 409:349 - 54; http://dx.doi.org/10.1038/35053086; PMID: 11201744
   PubMed Web of Science ®Google Scholar
• Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001; 276:47771 - 4; PMID: 11694501
   PubMed Web of Science ®Google Scholar
• ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002; 22:5662 - 8; http://dx.doi.org/10.1128/MCB.22.16.5662-5668.2002; PMID: 12138178
   PubMed Web of Science ®Google Scholar
• Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays 1999; 21:47 - 52; http://dx.doi.org/10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; PMID: 10070253
   PubMed Web of Science ®Google Scholar
• Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278:1803 - 5; http://dx.doi.org/10.1126/science.278.5344.1803; PMID: 9388184
   PubMed Web of Science ®Google Scholar
• Muromoto R, Nakao K, Watanabe T, Sato N, Sekine Y, Sugiyama K, et al. Physical and functional interactions between Daxx and STAT3. Oncogene 2006; 25:2131 - 6; http://dx.doi.org/10.1038/sj.onc.1209235; PMID: 16331268
   PubMed Web of Science ®Google Scholar
• Muromoto R, Kuroda M, Togi S, Sekine Y, Nanbo A, Shimoda K, et al. Functional involvement of Daxx in gp130-mediated cell growth and survival in BaF3 cells. Eur J Immunol 2010; http://dx.doi.org/10.1002/eji.201040688
   PubMed Web of Science ®Google Scholar
• Yamashina K, Yamamoto H, Chayama K, Nakajima K, Kikuchi A. Suppression of STAT3 activity by Duplin, which is a negative regulator of the Wnt signal. J Biochem 2006; 139:305 - 14; http://dx.doi.org/10.1093/jb/mvj033; PMID: 16452319
   PubMed Web of Science ®Google Scholar
• Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, et al. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 2005; 65:6701 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-05-0130; PMID: 16061651
   PubMed Web of Science ®Google Scholar
• Tsuruma R, Ohbayashi N, Kamitani S, Ikeda O, Sato N, Muromoto R, et al. Physical and functional interactions between STAT3 and KAP1. Oncogene 2008; 27:3054 - 9; http://dx.doi.org/10.1038/sj.onc.1210952; PMID: 18037959
   PubMed Web of Science ®Google Scholar
• Sekine Y, Tsuji S, Ikeda O, Sato N, Aoki N, Aoyama K, et al. Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene 2006; 25:5801 - 6; http://dx.doi.org/10.1038/sj.onc.1209578; PMID: 16636663
   PubMed Web of Science ®Google Scholar
• Zhang W, Zeng X, Briggs KJ, Beaty R, Simons B, Chiu Yen RW, et al. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene 2010; 29:2467 - 76; http://dx.doi.org/10.1038/onc.2010.12; PMID: 20154726
   PubMed Web of Science ®Google Scholar
• Foveau B, Boulay G, Pinte S, Van Rechem C, Rood BR, Leprince D. The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem 2012; 287:5366 - 78; http://dx.doi.org/10.1074/jbc.M111.329466; PMID: 22184117
   PubMed Web of Science ®Google Scholar
• Van Rechem C, Boulay G, Pinte S, Stankovic-Valentin N, Guérardel C, Leprince D. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 2010; 30:4045 - 59; http://dx.doi.org/10.1128/MCB.00582-09; PMID: 20547755
   PubMed Web of Science ®Google Scholar
• Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Guérardel C, et al. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem 2009; 284:20927 - 35; http://dx.doi.org/10.1074/jbc.M109.022350; PMID: 19525223
   PubMed Web of Science ®Google Scholar
• Boulay G, Malaquin N, Loison I, Foveau B, Van Rechem C, Rood BR, et al. Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation. J Biol Chem 2012; 287:5379 - 89; http://dx.doi.org/10.1074/jbc.M111.304287; PMID: 22194601
   PubMed Web of Science ®Google Scholar
• Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24:5552 - 60; http://dx.doi.org/10.1038/sj.onc.1208719; PMID: 16007214
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1 - 20; http://dx.doi.org/10.1042/BJ20030407; PMID: 12773095
   PubMed Web of Science ®Google Scholar
• Stankovic-Valentin N, Deltour S, Seeler J, Pinte S, Vergoten G, Guérardel C, et al. An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol 2007; 27:2661 - 75; http://dx.doi.org/10.1128/MCB.01098-06; PMID: 17283066
   PubMed Web of Science ®Google Scholar
• Wen Z, Zhong Z, Darnell JE Jr.. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82:241 - 50; http://dx.doi.org/10.1016/0092-8674(95)90311-9; PMID: 7543024
   PubMed Web of Science ®Google Scholar
• Hsieh YL, Kuo HY, Chang CC, Naik MT, Liao PH, Ho CC, et al. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response. EMBO J 2013; 32:791 - 804; http://dx.doi.org/10.1038/emboj.2013.5; PMID: 23395904
   PubMed Web of Science ®Google Scholar
• Chao TT, Chang CC, Shih HM. SUMO modification modulates the transrepression activity of PLZF. Biochem Biophys Res Commun 2007; 358:475 - 82; http://dx.doi.org/10.1016/j.bbrc.2007.04.157; PMID: 17498654
   PubMed Web of Science ®Google Scholar
• Lin DY, Lai MZ, Ann DK, Shih HM. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem 2003; 278:15958 - 65; http://dx.doi.org/10.1074/jbc.M300387200; PMID: 12595526
   PubMed Web of Science ®Google Scholar
• Chang CC, Naik MT, Huang YS, Jeng JC, Liao PH, Kuo HY, et al. Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell 2011; 42:62 - 74; http://dx.doi.org/10.1016/j.molcel.2011.02.022; PMID: 21474068
   PubMed Web of Science ®Google Scholar
• Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J 1990; 9:4477 - 84; PMID: 2176154
   PubMed Web of Science ®Google Scholar
• Chen KY, Huang LM, Kung HJ, Ann DK, Shih HM. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene 2004; 23:1854 - 62; http://dx.doi.org/10.1038/sj.onc.1207308; PMID: 14676838
   PubMed Web of Science ®Google Scholar
• Huang YS, Chang CC, Huang TC, Hsieh YL, Shih HM. Daxx interacts with and modulates the activity of CREB. Cell Cycle 2012; 11:99 - 108; http://dx.doi.org/10.4161/cc.11.1.18430; PMID: 22185778
   PubMed Web of Science ®Google Scholar